GlassScriptPhysician profile
Wesley J San
NPI 1376834838
$3,851.29
in general payments reported to CMS, 2019-2025
28 companies · $358 in 2025
The $358 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $338 · 2021: $329 · 2022: $896 · 2023: $775 · 2024: $771 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,904.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,618.18 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Abbvie INC. | $256.94 | 2021-2024 | Ubrelvy, Botox |
| Medtronic USA, INC. | $233.30 | 2019-2020 | |
| Nevro Corp. | $232.41 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $222.47 | 2022-2025 | Xeomin |
| Pfizer INC. | $165.87 | 2019-2024 | |
| Zimvie INC. | $148.38 | 2023 | |
| Si-Bone, INC. | $99.24 | 2019-2024 | |
| Allergan, INC. | $97.96 | 2019-2022 | |
| Pacira Therapeutics, INC. | $94.48 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $89.42 | 2022-2023 | Seglentis |
| Boston Scientific Corporation | $71.47 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $54.88 | 2025 | Purified Cortrophin Gel |
| Biohaven Pharmaceutical Holding Company LTD. | $50.27 | 2022 | |
| Orexo US, INC. | $49.53 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $46.99 | 2024-2025 | Evoke |
| Ipsen Biopharmaceuticals, INC | $37.54 | 2020 | |
| Novartis Pharmaceuticals Corporation | $36.34 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $31.47 | 2021 | |
| Otto Bock Healthcare LP | $30.72 | 2021 | |
| Fidia Pharma USA INC. | $29.76 | 2025 | Triluron, Hymovis |
| Catalyst Pharmaceuticals, INC. | $29.72 | 2020 | |
| Virtus Pharmaceuticals LLC | $27.05 | 2024 | Levorphanol Tartrate |
| Azurity Pharmaceuticals, INC. | $21.82 | 2024 | Horizant |
| Alexion Pharmaceuticals, INC. | $20.69 | 2021 | |
| Alnylam Pharmaceuticals INC. | $19.44 | 2019 | |
| Grt US Holding, INC. | $18.73 | 2020 | |
| Amgen INC. | $16.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley San listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.